AVAILABLE NOW! HANSOH PHARMA'S HENGMU (TENOFOVIR AMIBUFENAMIDE TABLETS) - A BREAKTHROUGH CLASS 1 HEPATITIS B DRUG LAUNCHES NATIONWIDE SUPPLY

On June 26, Hansoh Pharma's new Class 1 drug Hengmu (Tenofovir Amibufenamide Tablets) started nationwide supply. Hengmu is a new second-generation tenofovir independently developed by Hansoh Pharma, and also the first oral anti-hepatitis B virus (HBV) drug originally developed in China, for the treatment of adult patients with chronic hepatitis B. Compared with tenofovir disoproxil fumarate (TDF), Hengmu requires less than one-tenth the dose to achieve similar antiviral efficacy, and delivers comparable antiviral efficacy as first-line drugs and better bone and kidney safety. The launch of Hengmu will provide a new option for the treatment of hepatitis B in China. ▲ Hengmu (Tenofovir Amibufenamide Tablets) ▲ Good news for hepatitis B patients; Hengmu started nationwide supply Hengmu on the production line ▲ Strengthen lean management and provide whole-process drug quality and safety control to meet the medication requirements of hepatitis B patients with high quality Hengmu ready to go ▲ Race against time to accelerate accessibility and ensure supply; loading of Hengmu is under way in an intense and orderly manner. First shipment of Hengmu ▲ In response to patients' expectations for a better tomorrow, boxes of Hengmu are shipped to all parts of the country at full speed to protect patients' health with technological innovation.

The release as fetched from its publisher. hspharm.com ↗